-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is only for medical and pharmacy professionals to read and see if you have caught up with breast cancer "hot spots".
On December 10-12, 2021, the YBCSG "Double Twelfth" year-end conference of the Yangtze River Academic Belt and Breast Alliance was successfully held
.
The conference consisted of 13 experts from Zhang Jian, Li Hengyu, Ye Songqing, Wang Shouman, Nie Jianyun, Zheng Yabing, Qi Xiaowei, Xiong Huihua, Chen Wenyan, Liu Shu, Han Xinghua, Luo Ting, and Li Wei from various provinces in the Yangtze River Basin to form the presidium of the conference, and gathered famous national experts.
Experts and professors in the field of breast joint participation
.
At this meeting, YBCSG chairman and Professor Zhang Jian from Fudan University Cancer Hospital released the top ten "annual academic keywords" for breast cancer in 2021 for the first time
.
This keyword is based on the relevant abstract collections and reports of internationally renowned conferences such as the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), San Antonio Breast Cancer Research Conference (SABCS), etc.
Vocabulary
.
The announcement of this keyword reveals the hottest topic in the field of breast cancer diagnosis and treatment.
It not only inspires breast cancer clinical trials, but also brings the most cutting-edge diagnosis and treatment development to breast doctors and oncologists
.
The ten annual academic keywords are: CDK4/6 inhibitors, PD-1/PD-L1 inhibitors, HER2 antibody-conjugated drugs (ADC), tyrosine kinase inhibitors (TKI), PARP inhibitors, oral females Hormone receptor down-regulator (SERD), PI3K inhibitor, TROP-2 ADC, young breast cancer, brain metastasis
.
Let’s take a look at the specific analysis of these keywords: TOP 1: CDK4/6 inhibitors (CDK4/6i) This year, at ASCO, ESMO, SABCS and other international academic conferences, the clinical trial results of CDK4/6i were announced, including Overall survival (OS) data from multiple studies
.
At the same time, China's original CDK4/6i also released relevant data
.
In addition, the exploration of CDK4/6i biomarkers is also the focus of the medical community
.
Professor Li Wei from Jiangsu Provincial People's Hospital explained the cutting-edge progress of CDK4/6i at YBCSG
.
CDK4/6i combined with endocrine therapy is one of the treatment options for HR+ breast cancer patients
.
Since 2014, the research results of PALOMA-1, 2, 3, MONARCH-1, 2, MONALEESA-2, 3 have been announced, and CDK4/6i has gradually changed the treatment pattern of HR+HER2- advanced breast cancer patients
.
The phase III clinical trial results of PALOMA-2, MONALEESA-2, and MONARCH-3 show that CDK4/6i is effective for postmenopausal HR+ and HER2- advanced breast cancer patients, while the phase III clinical trial results of MNALEESA-7 show that the Patients with premenopausal/perimenopausal HR+ and HER2-advanced breast cancer undergoing endocrine therapy, ≤1 line chemotherapy, CDK4/6i also have survival benefits
.
CDK4/6i second-line treatment of HR+, HER2- advanced breast cancer patients also brings survival benefits to patients
.
The results of PALOMA-3, MONARCH-2, MONALEESA-3, and DWANA-1 all support that CDK4/6i combined with fulvestrant can effectively prolong the progression-free survival (PFS) of patients with HR+ and HER- advanced breast cancer
.
At present, CDK4/6i has been confirmed that both first-line and second-line treatment can make HR+, HER2- advanced breast cancer patients obtain long-term survival benefits
.
Major guidelines list CDK4/6i combination therapy as the first-line first-line treatment for patients with HR+, HER2- advanced breast cancer
.
TOP 2: PD-1/PD-L1 is the "main force" of immunotherapy, and PD-1/PD-L1 inhibitors are not allowed to become the second of the top ten academic keywords for breast cancer
.
It is worth noting that there have been many studies this year on whether PD-1/PD-L1 inhibitors are used in neoadjuvant therapy for patients with early breast cancer
.
In addition, the treatment of advanced triple-negative breast cancer (TNBC) with PD-1/PD-L1 inhibitors is also the focus of exploration
.
TOP 3: HER2-ADCADC drug has outstanding efficacy in the field of breast cancer diagnosis and treatment
.
Among them, DS8201 is more popular in early and advanced HER2+ breast cancer, while T-DM1 is another hot spot
.
In addition to these two HER2-ADCs, other HER2-ADCs are also under development
.
TOP 4: TKI Professor Zhang Jian introduced that the TKI-related research announced at the ASCO and ESMO conferences this year mainly focused on the use of TKI-assisted enhancement of early breast cancer, neoadjuvant treatment of large and small double targets, and the treatment sequence of late use of TKI
.
TOP 5: PARPi has also attracted much attention in the field of breast cancer diagnosis and treatment since the publication of the OlympiA research results
.
Multiple studies have confirmed that PAPRi has shown excellent efficacy in cancer patients with BRCA mutations
.
Professor Liu Yin from the Cancer Hospital of Fudan University brought a special report on "Olympia's Clear Sky-PARPi Exploration Road"
.
The results of the OlympiA study revealed that PARPi can prolong the median PFS (7.
0 months vs 4.
2 months) and median PFS2 (from random The time required for grouping to second-line treatment for disease progression or death from any cause) (13.
2 months vs 9.
3 months)
.
National Cancer Comprehensive Network (NCCN) guidelines recommend PARPi as the preferred option for advanced breast cancer with gBRCA mutations
.
However, platinum-containing chemotherapy also has a better effect in patients with advanced breast cancer with gBRCA mutations
.
At present, whether platinum-containing chemotherapy or PARPi can show better efficacy in advanced breast cancer with gBRCA mutations is still inconclusive
.
For gBRCA-mutated HER2-early high-risk breast cancer, NCCN guidelines recommend olaparib for one year of adjuvant intensive treatment
.
Professor Liu Yin said, will it be possible to identify the potential beneficiaries of PAPRi in the future? Can there be more combined treatment options? These are worthy of more exploration
.
TOP 6: Oral SERD Professor Zhang Jian said that at major conferences this year, the frequency of endocrine therapy drugs has declined
.
But as basic treatment drugs, endocrine treatment drugs are still very important
.
And oral SERD has gradually become a hot topic in breast cancer research
.
TOP 7: TROP-2 ADC This year, ASCO and ESMO announced the clinical research of TROP-2 ADC mainly focused on metastatic TNBC
.
Professor Zhang Jian said that among the TROP-2 ADC drugs, the most popular is Goxatuzumab (SG)
.
TOP 8: PI3Ki In recent years, PI3Ki new drug research progress has been rapid
.
In addition to the test data of these new drugs at the ASCO and ESMO conferences, there are also many PI3Ki under development in China
.
TOP 9: Young breast cancer In recent years, the trend of younger breast cancer has become prominent, so young breast cancer has attracted more and more attention
.
Major academic conferences have covered the clinical characteristics, endocrine therapy, and adjuvant chemotherapy regimens of young breast cancer patients
.
TOP 10: Brain metastasis The advanced treatment of breast cancer and brain metastasis is a difficult point in clinical treatment
.
And this part focuses on the treatment of advanced breast cancer brain metastases, and the determination of certain special drugs in the cerebrospinal fluid
.
Finally, Professor Zhang Jian pointed out that this year's top ten "annual academic keywords for breast cancer" included special reports from this year's important conferences, and the keyword evaluation system will be further improved in the future
.
In the future every year on Double 12, the Yangtze River Academic Belt and Breast Alliance will release the "Annual Academic Keywords" and continue to be with you
.
About the Yangtze River Academic Belt and Breast Alliance (YBCSG) The Yangtze River Academic Belt and Breast Alliance (YBCSG) is a branch group of the Yangtze River Academic Belt Oncology Group (YCOG).
It is committed to promoting academic exchanges in the diagnosis and treatment of breast cancer within and outside the Yangtze River Basin, and actively develops multi-center breast cancer.
Clinical research; to promote the continuing education, standardization and improvement of breast cancer practitioners
.
YBCSG opened twelve colleges, School of Breast Surgery, School of Radiotherapy, School of Targeting and Immunology, HER2 House, School of Support and Rehabilitation, School of Diagnostics, School of Clinical Research, School of Endocrinology, School of Genes and Genetics, School of Chemotherapy, New Auxiliary colleges, basic and transformation colleges have received widespread attention and praise
.
At present, Professor Zhang Jian from the Cancer Hospital of Fudan University serves as the chairman of YBCSG, and Professor Li Hengyu from the First Affiliated Hospital of Naval Military Medical University serves as the deputy chairman and secretary-general of YBCSG.
Professor Li Wei, Professor Zheng Yabing, Professor Ye Songqing, and Han Xinghua from all provinces and cities of the alliance Professors, Professor Chen Wenyan, Professor Xiong Huihua, Professor Wang Shouman, Professor Qi Xiaowei, Professor Luo Ting, Professor Nie Jianyun, and Professor Liu Shu served as the deputy directors
.
Focus on doctors, focus on patients, on medical media ("medical circles") "Medical circles" is a leading new medical media and doctor service platform in China.
Timely and reliable content.
At present, it has more than 20 clinical specialist WeChat subscription accounts, such as the medical oncology channel, the medical blood channel, and the medical cancer club.
More than 10 million users have subscribed
.
The "Medical Doctors Station APP" launched by the "Medical Circle" is mainly to provide doctors with medical information, expert live broadcasts, clinical courses, examination question banks and other high-quality content, and is equipped with medication queries and guidelines to assist doctors in clinical decision-making.
Up to now More than 2.
5 million registered users
.
On December 10-12, 2021, the YBCSG "Double Twelfth" year-end conference of the Yangtze River Academic Belt and Breast Alliance was successfully held
.
The conference consisted of 13 experts from Zhang Jian, Li Hengyu, Ye Songqing, Wang Shouman, Nie Jianyun, Zheng Yabing, Qi Xiaowei, Xiong Huihua, Chen Wenyan, Liu Shu, Han Xinghua, Luo Ting, and Li Wei from various provinces in the Yangtze River Basin to form the presidium of the conference, and gathered famous national experts.
Experts and professors in the field of breast joint participation
.
At this meeting, YBCSG chairman and Professor Zhang Jian from Fudan University Cancer Hospital released the top ten "annual academic keywords" for breast cancer in 2021 for the first time
.
This keyword is based on the relevant abstract collections and reports of internationally renowned conferences such as the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), San Antonio Breast Cancer Research Conference (SABCS), etc.
Vocabulary
.
The announcement of this keyword reveals the hottest topic in the field of breast cancer diagnosis and treatment.
It not only inspires breast cancer clinical trials, but also brings the most cutting-edge diagnosis and treatment development to breast doctors and oncologists
.
The ten annual academic keywords are: CDK4/6 inhibitors, PD-1/PD-L1 inhibitors, HER2 antibody-conjugated drugs (ADC), tyrosine kinase inhibitors (TKI), PARP inhibitors, oral females Hormone receptor down-regulator (SERD), PI3K inhibitor, TROP-2 ADC, young breast cancer, brain metastasis
.
Let’s take a look at the specific analysis of these keywords: TOP 1: CDK4/6 inhibitors (CDK4/6i) This year, at ASCO, ESMO, SABCS and other international academic conferences, the clinical trial results of CDK4/6i were announced, including Overall survival (OS) data from multiple studies
.
At the same time, China's original CDK4/6i also released relevant data
.
In addition, the exploration of CDK4/6i biomarkers is also the focus of the medical community
.
Professor Li Wei from Jiangsu Provincial People's Hospital explained the cutting-edge progress of CDK4/6i at YBCSG
.
CDK4/6i combined with endocrine therapy is one of the treatment options for HR+ breast cancer patients
.
Since 2014, the research results of PALOMA-1, 2, 3, MONARCH-1, 2, MONALEESA-2, 3 have been announced, and CDK4/6i has gradually changed the treatment pattern of HR+HER2- advanced breast cancer patients
.
The phase III clinical trial results of PALOMA-2, MONALEESA-2, and MONARCH-3 show that CDK4/6i is effective for postmenopausal HR+ and HER2- advanced breast cancer patients, while the phase III clinical trial results of MNALEESA-7 show that the Patients with premenopausal/perimenopausal HR+ and HER2-advanced breast cancer undergoing endocrine therapy, ≤1 line chemotherapy, CDK4/6i also have survival benefits
.
CDK4/6i second-line treatment of HR+, HER2- advanced breast cancer patients also brings survival benefits to patients
.
The results of PALOMA-3, MONARCH-2, MONALEESA-3, and DWANA-1 all support that CDK4/6i combined with fulvestrant can effectively prolong the progression-free survival (PFS) of patients with HR+ and HER- advanced breast cancer
.
At present, CDK4/6i has been confirmed that both first-line and second-line treatment can make HR+, HER2- advanced breast cancer patients obtain long-term survival benefits
.
Major guidelines list CDK4/6i combination therapy as the first-line first-line treatment for patients with HR+, HER2- advanced breast cancer
.
TOP 2: PD-1/PD-L1 is the "main force" of immunotherapy, and PD-1/PD-L1 inhibitors are not allowed to become the second of the top ten academic keywords for breast cancer
.
It is worth noting that there have been many studies this year on whether PD-1/PD-L1 inhibitors are used in neoadjuvant therapy for patients with early breast cancer
.
In addition, the treatment of advanced triple-negative breast cancer (TNBC) with PD-1/PD-L1 inhibitors is also the focus of exploration
.
TOP 3: HER2-ADCADC drug has outstanding efficacy in the field of breast cancer diagnosis and treatment
.
Among them, DS8201 is more popular in early and advanced HER2+ breast cancer, while T-DM1 is another hot spot
.
In addition to these two HER2-ADCs, other HER2-ADCs are also under development
.
TOP 4: TKI Professor Zhang Jian introduced that the TKI-related research announced at the ASCO and ESMO conferences this year mainly focused on the use of TKI-assisted enhancement of early breast cancer, neoadjuvant treatment of large and small double targets, and the treatment sequence of late use of TKI
.
TOP 5: PARPi has also attracted much attention in the field of breast cancer diagnosis and treatment since the publication of the OlympiA research results
.
Multiple studies have confirmed that PAPRi has shown excellent efficacy in cancer patients with BRCA mutations
.
Professor Liu Yin from the Cancer Hospital of Fudan University brought a special report on "Olympia's Clear Sky-PARPi Exploration Road"
.
The results of the OlympiA study revealed that PARPi can prolong the median PFS (7.
0 months vs 4.
2 months) and median PFS2 (from random The time required for grouping to second-line treatment for disease progression or death from any cause) (13.
2 months vs 9.
3 months)
.
National Cancer Comprehensive Network (NCCN) guidelines recommend PARPi as the preferred option for advanced breast cancer with gBRCA mutations
.
However, platinum-containing chemotherapy also has a better effect in patients with advanced breast cancer with gBRCA mutations
.
At present, whether platinum-containing chemotherapy or PARPi can show better efficacy in advanced breast cancer with gBRCA mutations is still inconclusive
.
For gBRCA-mutated HER2-early high-risk breast cancer, NCCN guidelines recommend olaparib for one year of adjuvant intensive treatment
.
Professor Liu Yin said, will it be possible to identify the potential beneficiaries of PAPRi in the future? Can there be more combined treatment options? These are worthy of more exploration
.
TOP 6: Oral SERD Professor Zhang Jian said that at major conferences this year, the frequency of endocrine therapy drugs has declined
.
But as basic treatment drugs, endocrine treatment drugs are still very important
.
And oral SERD has gradually become a hot topic in breast cancer research
.
TOP 7: TROP-2 ADC This year, ASCO and ESMO announced the clinical research of TROP-2 ADC mainly focused on metastatic TNBC
.
Professor Zhang Jian said that among the TROP-2 ADC drugs, the most popular is Goxatuzumab (SG)
.
TOP 8: PI3Ki In recent years, PI3Ki new drug research progress has been rapid
.
In addition to the test data of these new drugs at the ASCO and ESMO conferences, there are also many PI3Ki under development in China
.
TOP 9: Young breast cancer In recent years, the trend of younger breast cancer has become prominent, so young breast cancer has attracted more and more attention
.
Major academic conferences have covered the clinical characteristics, endocrine therapy, and adjuvant chemotherapy regimens of young breast cancer patients
.
TOP 10: Brain metastasis The advanced treatment of breast cancer and brain metastasis is a difficult point in clinical treatment
.
And this part focuses on the treatment of advanced breast cancer brain metastases, and the determination of certain special drugs in the cerebrospinal fluid
.
Finally, Professor Zhang Jian pointed out that this year's top ten "annual academic keywords for breast cancer" included special reports from this year's important conferences, and the keyword evaluation system will be further improved in the future
.
In the future every year on Double 12, the Yangtze River Academic Belt and Breast Alliance will release the "Annual Academic Keywords" and continue to be with you
.
About the Yangtze River Academic Belt and Breast Alliance (YBCSG) The Yangtze River Academic Belt and Breast Alliance (YBCSG) is a branch group of the Yangtze River Academic Belt Oncology Group (YCOG).
It is committed to promoting academic exchanges in the diagnosis and treatment of breast cancer within and outside the Yangtze River Basin, and actively develops multi-center breast cancer.
Clinical research; to promote the continuing education, standardization and improvement of breast cancer practitioners
.
YBCSG opened twelve colleges, School of Breast Surgery, School of Radiotherapy, School of Targeting and Immunology, HER2 House, School of Support and Rehabilitation, School of Diagnostics, School of Clinical Research, School of Endocrinology, School of Genes and Genetics, School of Chemotherapy, New Auxiliary colleges, basic and transformation colleges have received widespread attention and praise
.
At present, Professor Zhang Jian from the Cancer Hospital of Fudan University serves as the chairman of YBCSG, and Professor Li Hengyu from the First Affiliated Hospital of Naval Military Medical University serves as the deputy chairman and secretary-general of YBCSG.
Professor Li Wei, Professor Zheng Yabing, Professor Ye Songqing, and Han Xinghua from all provinces and cities of the alliance Professors, Professor Chen Wenyan, Professor Xiong Huihua, Professor Wang Shouman, Professor Qi Xiaowei, Professor Luo Ting, Professor Nie Jianyun, and Professor Liu Shu served as the deputy directors
.
Focus on doctors, focus on patients, on medical media ("medical circles") "Medical circles" is a leading new medical media and doctor service platform in China.
Timely and reliable content.
At present, it has more than 20 clinical specialist WeChat subscription accounts, such as the medical oncology channel, the medical blood channel, and the medical cancer club.
More than 10 million users have subscribed
.
The "Medical Doctors Station APP" launched by the "Medical Circle" is mainly to provide doctors with medical information, expert live broadcasts, clinical courses, examination question banks and other high-quality content, and is equipped with medication queries and guidelines to assist doctors in clinical decision-making.
Up to now More than 2.
5 million registered users
.
